Literature DB >> 16966800

Prolonged outbreak of B meningococcal disease in the Seine-Maritime department, France, January 2003 to June 2005.

P Rouaud1, A Perrocheau, M K Taha, C Sesboué, A M Forgues, I Parent du Châtelet, Daniel Levy-Bruhl.   

Abstract

Between January 2003 and June 2005, an outbreak of meningococcal disease occurred in the department of Seine-Maritime in northern France. Eighty six cases were notified, giving an average annual incidence of 2.7 cases per 100,000 inhabitants, compared with 1.6 in France. An especially affected area was defined as the city of Dieppe and its surrounding area (26 cases, giving an annual incidence of 12 cases per 100,000). This outbreak was due to N. meningitidis phenotype B:14:P1.7,16 belonging to the clonal complex ST-32/ET-5. Over the 31 B14:P1.7,16 cases confirmed by phenotyping methods at the national reference centre for meningococci (CNR, Centre National de Reference des meningocoques) the case-fatality rate (19%) and the proportion of purpura fulminans (42%) were especially high. Teenagers aged between 15 and 19 years and children aged 1 to 9 years were the most affected. In 2003, health authorities put in place enhanced epidemiological surveillance and informed practitioners and population about the disease. In 2004, the national vaccination advisory board studied the opportunity of using a non licensed outer membrane vesicle vaccine developed in Norway which may be effective against the B14:P1.7,16 strain. The Ministry of health decided in 2006 to offer vaccination with this vaccine to people aged 1 to 19 years in Seine-Maritime.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16966800

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  8 in total

Review 1.  Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses?

Authors:  Dan M Granoff; Sanjay Ram; Peter T Beernink
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

Review 2.  The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology.

Authors:  Vanessa N Racloz; Silva J D Luiz
Journal:  BMC Infect Dis       Date:  2010-06-17       Impact factor: 3.090

3.  Persistence of hyperinvasive meningococcal strain types during global spread as recorded in the PubMLST database.

Authors:  Eleanor R Watkins; Martin C J Maiden
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

4.  Genomic Analysis of the Evolution and Global Spread of Hyper-invasive Meningococcal Lineage 5.

Authors:  Odile B Harrison; James E Bray; Martin C J Maiden; Dominique A Caugant
Journal:  EBioMedicine       Date:  2015-03-01       Impact factor: 8.143

Review 5.  Vaccine development against Neisseria meningitidis.

Authors:  Ulrich Vogel; Heike Claus
Journal:  Microb Biotechnol       Date:  2011-01       Impact factor: 5.813

6.  Outbreak of invasive meningococcal disease caused by a meningococcus serogroup B in a nursery school, Wallonia, Belgium, 2018.

Authors:  Stéphanie Jacquinet; Wesley Mattheus; Sophie Quoilin; Chloé Wyndham-Thomas; Charlotte Martin; Dimitri Van der Linden; André Mulder; Julie Frère; Carole Schirvel
Journal:  Euro Surveill       Date:  2022-03

7.  A decade of invasive meningococcal disease surveillance in Poland.

Authors:  Anna Skoczyńska; Izabela Waśko; Alicja Kuch; Marcin Kadłubowski; Agnieszka Gołębiewska; Małgorzata Foryś; Marlena Markowska; Patrycja Ronkiewicz; Katarzyna Wasiak; Aleksandra Kozińska; Bożena Matynia; Waleria Hryniewicz
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

8.  Targeted vaccination campaigns of teenagers after two clusters of B invasive meningococcal disease in Brittany, France, 2017.

Authors:  Mathilde Pivette; Muhamed-Kheir Taha; Anne-Sophie Barret; Elisabeth Polard; Marie-Bernadette Hautier; Jean-Benoît Dufour; Marlène Faisant; Lisa Antoinette King; Denise Antona; Daniel Levy-Bruhl; Hélène Tillaut; Alexandre Scanff; Camille Morival; José-Hector Aranda Grau; Pierre Guillaumot; Bertrand Gagnière
Journal:  BMC Public Health       Date:  2020-09-10       Impact factor: 3.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.